|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Hematology Annual Meeting in Orlando.
|
|
|
 |
|
6 DECEMBER 2010
|
| |
|
This expert roundtable with Michel Attal, MD, PhD, from Centre Hospitalier de Purpan in Toulouse, France; Antonio Palumbo, MD, from the University of Torino in Torino, Italy; Philip McCarthy Jr, MD, from Roswell Park Cancer Institute in Buffalo, New York, United States; and Kenneth Anderson, MD, from the Dana-Farber Cancer Institute in Boston, Massachusetts, United States, discusses newly released data concerning the role of maintenance therapy for multiple myeloma focusing on the following data releases:
Abstract #37: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplant (AHSCT) for multiple myeloma (MM): CALGB 100104.
Abstract #310: Maintenance treatment with lenalidomide after transplantation for myeloma: Final Analysis of the IFM 2005-02.
Abstract #622: A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens
|
| |
|
|
| |
|
View the Expert Roundtable discussion and downloadable slides 
View eNewsflash
|
 |
|
7 DECEMBER 2010
|
| |
|
This expert interview with Timothy Hughes, MD, MBBS, from the Royal Adelaide Hospital in Adelaide, Australia, and Elias Jabbour, MD, from the M. D. Anderson Cancer Center in Houston, Texas, United States, discusses newly released data concerning the 24-month follow-up of the phase III randomized clinical trial evaluating nilotinib in patients with newly diagnosed Ph+ CML (ENESTnd).
Abstract #207: ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed CML in chronic phase (CML-CP) |
| |
|
|
| |
|
View the Expert Interview and downloadable slides
View eNewsflash |
|
|
|
|
|
|
